Matulane (procarbazine hydrochloride) / Leadiant Biosci - LARVOL DELTA

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. (PubMed, Lancet) - P3 | "BrECADD guided by PET after two cycles is better tolerated and more effective than eBEACOPP in first-line treatment of adult patients with advanced-stage, classical Hodgkin lymphoma."

Journal • Metastases • P3 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies (ASH 2025) - "Patients deemed adequately fit were assigned to receive the standard combination of HDMTX,procarbazine, and rituximab as induction therapy...Patients ineligible for HDMTX wereassigned to receive concomitant whole-brain radiotherapy, temozolomide, and rituximab as inductiontherapy, followed by maintenance temozolomide (Part B)...The 3-year OS was 44 (±16%) forprocarbazine and 54 (±14%) for lenalidomide... Risk of treatment failure (in terms of dropout and survival rates) appeared higher comparedto the PRIMAIN trial. Discrepancies in feasibility and efficacy between PRIMAIN and FIORELLA trialsgenerate some concerns about generalization of results of PCNSL trials among different geographicalregions.These unexpected outcomes offer several valuable lessons on the incorporation of comorbidity indexesinto trial eligibility/stratification and the relevance of interim analyses to inform ethical decisions early."

Clinical • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Subarachnoid Hemorrhage

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (clinicaltrials.gov) - P2 | N=65 | Recruiting | Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Trial initiation date • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Transplantation

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL) (ASH 2025) - P1/2 | "Background : With standard high-dose methotrexate (HDMTX) and cytarabine (HDAraC)-basedinductions, half of the patients achieved complete response (CR)...Responders received two cycles of HDAraCfollowed by HD thiotepa-busulfan and ASCT... Both arms met the predetermined threshold of efficacy with 86% and 82% of CR/CRurates in the lenalidomide and ibrutinib arm, respectively. R-MPV plus a BTK-inhibitor or animmunomodulatory drug constitutes an interesting first-line induction for PCNSL patients up to 65 years.Correlation of patient, disease and lymphoid subpopulations characteristics with response in eachtreatment arm will be explored to guide the choice of the targeted therapy. Ancillary studies regardingthe prognostic impact of baseline and end of induction levels of cytokines in the CSF, ctDNA inplasma/CSF and radiomic features, as biomarkers of response, are planned."

Clinical • IO biomarker • P2 data • CNS Disorders • CNS Lymphoma • Hematological Malignancies • Hepatology • Lymphoma • Mental Retardation • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Steven-Johnson Syndrome • CD4 • ICOS • PD-1

T-cell transcriptome affected by therapy-related clonal hematopoiesis in long-term survivors of pediatric cancers (AACR 2026) - "STAT3 Y640F, a hotspot mutation specifically linked to prior exposure to procarbazine in Hodgkin Lymphoma (HL) survivors, was most frequent in the SJLIFE cohort...To our best knowledge, this is the first study that shows CH mutation can confer selective advantage to specific functional cell subsets of CD8 T-cells and analysis of gene-regulatory network changes related to STAT3 Y640F mutation in those cell subpopulations is currently ongoing. Our study also demonstrates that cell sorting followed by scKinnex can be an effective strategy for studying the functional impact of rare CH mutations at the single cell resolution in relevant cell types."

Clinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • CD8 • GZMB • GZMH • JUNB • NKG7 • STAT3

Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study (ASH 2025) - "In the GHSG HD21 trial for advanced-stage classic Hodgkin lymphoma (AS-cHL), patients received polychemotherapy regimens (eBEACOPP[bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone] orBrECADD [brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, anddexamethasone]) with a risk to develop febrile neutropenia (FN) and/or infections. This comprehensive analysis of the HD21 trial demonstrates the efficacy of ABP and peg G-CSF in thetreatment of AS-cHL in preventing FN and higher-grade infections. This effect is most pronounced in thefirst cycle and in patients receiving BrECADD. Based on these results, we recommend the use of ABPduring the first cycle of the BrECADD regimen, at least."

Clinical • Metastases • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL). (PubMed, Neuro Oncol) - "R-MVP/i was well tolerated and associated with excellent disease control and survival."

Journal • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Thrombocytopenia • Transplantation

Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma. (PubMed, Neuro Oncol) - "R-MPV-A is a highly efficacious and safe regimen with or without LD-WBRT. LD-WBRT contributes to disease control and increases PFS in PCNSL."

Journal • P2 data • Brain Cancer • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Charles Bonnet Syndrome After Radiation (AAN 2026) - "Few cases of CBS as a side effect of radiation have been described but it is likely under reported.Design/ N/A Case Report: A 33-year-old male with a right frontal/ corpus callosum grade 2 oligodendroglioma, IDH MT, 1p/19q codeleted underwent a subtotal resection followed by radiation alone and four cycles of procarbazine, lomustine, and vincristine chemotherapy. Our case underscores the potential for CBS to emerge as a complication of radiation, especially in patients experiencing cognitive decline. Although rare, clinicians should consider CBS as a complication of RION."

Brain Cancer • Glioma • Head and Neck Cancer • Ocular Inflammation • Oligodendroglioma • Ophthalmology • Optic Neuritis • Rare Diseases • Solid Tumor

Can omegaven avoid the destructive effect of procarbazine over ovarian reserve? (ISGE 2026) - "Omegaven is a promising drug for prevention of procarbazine's adverse effects on ovarian reserve. Further clinical studies must be conducted to make this experimental preventive treatment to become a routine practice."

CASP3 • IL6 • TNFA

CA082-1215: Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervous System Lymphoma (clinicaltrialsregister.eu) - P1/2 | N=31 | Recruiting | Sponsor: Bristol-Myers Squibb Services Unlimited Company

New P1/2 trial • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Transplantation

HD21 for Advanced Stages (clinicaltrials.gov) - P3 | N=1500 | Recruiting | Sponsor: University of Cologne | Trial primary completion date: Jun 2020 ➔ Jun 2021

Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

HD21 for Advanced Stages (clinicaltrials.gov) - P3 | N=1500 | Not yet recruiting | Sponsor: University of Cologne | Initiation date: Apr 2016 ➔ Jul 2016

Trial initiation date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

HD21 for Advanced Stages (clinicaltrials.gov) - P3 | N=1500 | Not yet recruiting | Sponsor: University of Cologne

New P3 trial • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

HD21 for Advanced Stages (clinicaltrials.gov) - P3 | N=1500 | Recruiting | Sponsor: University of Cologne | Not yet recruiting ➔ Recruiting

Enrollment open • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

HD21 for Advanced Stages (clinicaltrials.gov) - P3 | N=1500 | Active, not recruiting | Sponsor: University of Cologne | Recruiting ➔ Active, not recruiting

Enrollment closed • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

HD21 for Advanced Stages (clinicaltrials.gov) - P3 | N=1500 | Recruiting | Sponsor: University of Cologne | Trial primary completion date: Jun 2021 ➔ Dec 2022

Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

HD21 for Advanced Stages (clinicaltrials.gov) - P3 | N=1500 | Recruiting | Sponsor: University of Cologne | Trial primary completion date: Mar 2020 ➔ Jun 2020

Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

High-Dose Methotrexate Containing Induction Chemotherapy Followed By Nivolumab Consolidation in Older (≥ 65) Patients with Previously Untreated Primary CNS Lymphoma (ASH 2023) - P1 | "Variations of the following regimens were used for induction: 43% R-MPV (rituximab, methotrexate, procarbazine, and vincristine) (43%), 29% MRT (methotrexate, rituximab, and temozolomide), 21% MR (methotrexate and rituximab), and 7% MATRix (methotrexate, cytarabine, thiotepa, and rituximab)... The current study demonstrates encouraging safety and clinical outcomes of nivolumab consolidation in older PCNSL patients who are deemed poor candidates for ASCT or WBI. No DLT was observed during the safety run-in phase, and there was no unexpected toxicity associated with nivolumab although 1 patient discontinued the study treatment due to Stevens-Johnson syndrome, a rare but known AE associated with nivolumab, after Cycle 1. Overall, nivolumab consolidation was associated with favorable survival rates in a group of patients with poor-risk PCNSL."

Clinical • Acute Kidney Injury • CNS Lymphoma • Fatigue • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Nephrology • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Renal Disease • Septic Shock • Steven-Johnson Syndrome

Mapping the molecular landscape of glioblastoma: Pathogenesis, therapeutic targets and bioactive interventions. (PubMed, Crit Rev Oncol Hematol) - "First-line therapy includes surgery followed by the primary chemotherapeutic agent temozolomide in combination with radiotherapy. Other drugs, including bevacizumab, carmustine, and the combination of procarbazine, lomustine, and vincristine, offer limited benefits...This review emphasizes the importance of systematic molecular mapping of GBM progression to identify the genetic, metabolic, and regulatory mechanisms that sustain malignancy and therapeutic resistance. Additionally, it also discusses the multimodal mechanism of natural bioactives that align with the overlapping molecular targets and pathways to overcome the limitations of single-target therapies, offering translational combination therapies that provide more effective and precision-based interventions for GBM management."

Journal • Review • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Consolidation reduced-dose whole-brain radiation therapy with response-adapted boost in older patients with newly diagnosed primary central nervous system lymphoma. (PubMed, J Neurooncol) - "Reduced-dose WBRT (23.4 Gy) combined with a response-adapted focal boost was associated with favorable survival and sustained functional preservation, even in elderly or low-PS patients. This strategy may be an effective and feasible consolidation option for frail older patients with PCNSL."

Journal • Retrospective data • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

CONCURRENT CHRONIC MYELOID LEUKEMIA AND OLIGODENDROGLIOMA: A CASE REPORT (WRMC 2026) - "Tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib are first-line in chronic phase...Standard care for grade 2 disease includes radiotherapy (RT) plus procarbazine, lomustine, and vincristine (PCV); temozolomide (TMZ) is an emerging alternative, and recent data support RT plus TMZ in select grade 2 gliomas...Close CBC monitoring and coordinated scheduling reduce toxicity. This report adds to the limited pool of data on dual malignancies and supports structured surveillance during perioperative and chemoradiation periods."

Case report • Clinical • Brain Cancer • Chronic Myeloid Leukemia • Glioma • Hematological Malignancies • Infectious Disease • Leukemia • Movement Disorders • Oligodendroglioma • Solid Tumor • ABL1 • BCR • IDH1

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (clinicaltrials.gov) - P1/2 | N=93 | Completed | Sponsor: Memorial Sloan Kettering Cancer Center | Recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Jan 2026 | Trial primary completion date: Dec 2026 ➔ Jan 2026

Trial completion • Trial completion date • Trial primary completion date • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma

ImproveCodel: A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (clinicaltrials.gov) - P3 | N=406 | Recruiting | Sponsor: University Hospital Heidelberg | Trial completion date: Mar 2031 ➔ Mar 2033 | Trial primary completion date: Mar 2031 ➔ Mar 2033

HEOR • Trial completion date • Trial primary completion date • Brain Cancer • Glioma • Hematological Disorders • Oligodendroglioma • Oncology • Solid Tumor

THE RANDOMIZED STUDY GHSG HD21 SHOWS SUPERIOR TOLERABILITY AND EFFICACY OF BRECADD VERSUS BEACOPP IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA (EHA 2024) - P3 | "Background:We hypothesized that therapy with the novel BrECADD regimen (brentuximab vedotin, etoposide,cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) guided by positron emission tomography aftertwo cycles (PET2) could improve the treatment of advanced-stage classical Hodgkin lymphoma (AS-cHL). TheHD21 trial aimed at demonstrating superiority over the intensified BEACOPP regimen (bleomycin, etoposide,doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) in terms of treatment-related morbidity(TRMB) and non-inferiority (NI) in terms of progression-free survival (PFS)...BrECADD is significantly more effective than BEACOPP and is associated with an unprecedentedly high 4-yearPFS, reducing the risk of progression/relapse by a third. Together with an abbreviated treatment duration forthe majority of patients and a favorable tolerability and feasibility profile, treatment with PET2-individualizedBrECADD sets a new benchmark for the treatment of..."

Clinical • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology